Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab

BACKGROUND: The optimal treatment sequence for patients with advanced BRAF V600 mutant melanoma is unknown. BRAF/MEK inhibition (BRAF/MEKi), single agent anti‐PD‐1 (aPD‐1) antibodies and combination immune checkpoint inhibition with nivolumab and ipilimumab (niv/ipi) are all approved; however, they...

Descripción completa

Detalles Bibliográficos
Autores principales: Moser, Justin C., Chen, Danli, Hu‐Lieskovan, Siwen, Grossmann, Kenneth F., Patel, Shiven, Colonna, Sarah V., Ying, Jian, Hyngstrom, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912019/
https://www.ncbi.nlm.nih.gov/pubmed/31677253
http://dx.doi.org/10.1002/cam4.2625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912019/
https://www.ncbi.nlm.nih.gov/pubmed/31677253
http://dx.doi.org/10.1002/cam4.2625

Ejemplares similares